Table 1.

Summary of patient characteristics

Patient no.	Gender	Age (years)	Stage	Metastasis	Chemotherapy	TRT before PET 2	EORTC response	PERCIST response	Progression-free survival (days)	Overall survival (days)	Death
1	M	80	LD	NM	CP	x	PMR	PMR	340	424	–
2	F	61	ED	B	EP	–	PMR	PMR	360	420	–
3	M	65	LD	NM	EP	–	PMD	PMD	88	307	x
4	M	62	ED	NM, L, B, A	EP	–	SMD	SMD	198	198	–
5	M	62	ED	NM, L, B	EP	–	PMR	PMR	188	408	x
6	M	48	ED	NM, L, B	EP	–	PMD	PMD	224	329	–
7	M	57	LD	B	EP	x	CMR	CMR	381	675	x
8	M	52	LD	NM	EP	x	PMR	PMR	328	500	x
9	F	60	ED	NM, L, B	EP	–	SMD	SMD	202	225	x
10	F	55	ED	NM	EP	–	PMR	PMR	160	160	–
11	M	66	LD	NM	CAV	x	PMD	PMD	79	162	x
12	M	66	LD	–	CP	x	PMD	PMD	160	347	–
13	M	54	LD	NM	EP	x	PMR	PMR	1028	1566	–
14	F	51	LD	–	EP	x	SMD	SMD	1363	1363	–
15	M	71	LD	NM	EP	x	SMD	SMD	360	1163	x
16	F	76	ED	A	EP	–	PMR	PMR	265	265	–
17	M	51	LD	–	EP	x	CMR	CMR	1241	1241	–
18	M	59	LD	–	EP	x	CMR	CMR	1386	1386	–
19	M	43	LD	–	CP	x	CMR	CMR	513	590	x
20	M	76	LD	–	EP	x	CMR	CMR	1344	1344	–
21	F	61	ED	A	EP	x	PMD	PMD	234	711	x
22	F	48	LD	–	EP	x	CMR	CMR	260	260	–
23	M	52	ED	NM, L, B	EP	–	PMD	PMD	158	201	x
24	M	69	ED	L, B	EP	–	SMD	SMD	167	251	–
25	F	51	ED	B	EP	–	PMR	PMR	151	405	x
26	M	55	LD	NM	EP	x	PMD	PMD	264	557	–
27	M	51	LD	–	EP	x	CMR	CMR	1615	1615	–
28	F	62	ED	L	EP	x	CMR	CMR	465	1149	–
29	F	65	ED	NM, L	CAV	x	PMR	PMR	209	408	x

A, adrenal gland; B, bone; NM, nodal metastasis; L, liver; EP, etoposide and cisplatin; CAV, cyclophosphamide, adriamycin and vincristine; CMR, complete metabolic response; PMR, partial metabolic response; SMD, stable metabolic disease; PMD, progressive metabolic disease.